InMed Pharmaceuticals (INM) Cost of Revenue (2021 - 2025)
InMed Pharmaceuticals (INM) posted quarterly Cost of Revenue of $635994.0 for Q4 2025, down 2.28% year-over-year from $650813.0 in Q4 2024, and down 11.29% quarter-over-quarter from $716962.0 in Q3 2025.
InMed Pharmaceuticals (INM) Cost of Revenue (2021 - 2025) Analysis & Trends
InMed Pharmaceuticals' Cost of Revenue history runs 5 years deep, the most recent figure standing at $635994.0 for Q4 2025.
- In Q4 2025, Cost of Revenue fell 2.28% year-over-year to $635994.0; the TTM figure through Dec 2025 stood at $3.2 million (up 1.43% YoY), while the FY2025 annual figure was $3.2 million, down 7.46% from the prior year.
- Cost of Revenue for Q4 2025 stood at $635994.0, down from $716962.0 in the prior quarter.
- The five-year high for Cost of Revenue was $1.3 million in Q2 2023, with the low at $127308.0 in Q1 2022.
- The 5-year median for Cost of Revenue is $728056.0 (2025), against an average of $668484.4.
- The sharpest annual moves came in 2023 and 2024: Cost of Revenue jumped 560.93% in 2023, then plunged 37.99% in 2024.
- InMed Pharmaceuticals' Cost of Revenue stood at $153537.0 in 2021, then soared by 120.55% to $338620.0 in 2022, then soared by 170.53% to $916058.0 in 2023, then dropped by 28.96% to $650813.0 in 2024, then decreased by 2.28% to $635994.0 in 2025.
- Business Quant data shows INM's Cost of Revenue at $635994.0 in Q4 2025, $716962.0 in Q3 2025, and $728056.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cost of Rev (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.81 Bn | 42.84 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.29 Bn | 39.63 Bn | 2.15 Bn | 1.99 Bn |
| 3 | Zoetis | 31.59 Bn | 29.91 Bn | 1.05 Bn | 673.00 Mn |
| 4 | Takeda Pharmaceutical | 28.67 Bn | 22.88 Bn | 5.10 Bn | 2.55 Bn |
| 5 | United Therapeutics | 22.24 Bn | 19.58 Bn | 683.80 Mn | 99.50 Mn |
| 6 | Viatris | 18.79 Bn | 17.91 Bn | 1.46 Bn | 2.30 Bn |
| 7 | Neurocrine Biosciences | 15.71 Bn | 15.32 Bn | 935.80 Mn | 23.20 Mn |
| 8 | Elanco Animal Health | 12.09 Bn | 11.56 Bn | 798.00 Mn | 570.00 Mn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.95 Bn | - | - |
| 10 | InMed Pharmaceuticals | 6.52 Mn | 1.28 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 635,994.00 |
| Dec 31, 2025 | 635,994.00 |
| Sep 30, 2025 | 716,962.00 |
| Sep 30, 2025 | 716,962.00 |
| Jun 30, 2025 | 728,056.00 |
| Jun 30, 2025 | 728,056.00 |
| Mar 31, 2025 | 1.09 Mn |
| Mar 31, 2025 | 1.09 Mn |
| Dec 31, 2024 | 650,813.00 |
| Dec 31, 2024 | 650,813.00 |
| Sep 30, 2024 | 771,225.00 |
| Sep 30, 2024 | 771,225.00 |
| Jun 30, 2024 | 816,996.00 |
| Jun 30, 2024 | 816,996.00 |
| Mar 31, 2024 | 883,143.00 |
| Mar 31, 2024 | 883,143.00 |
| Dec 31, 2023 | 916,058.00 |
| Dec 31, 2023 | 916,058.00 |
| Sep 30, 2023 | 880,620.00 |
| Sep 30, 2023 | 880,620.00 |